NF-kB Signaling Pathway in Neurodegeneration

Introduction

The NF-κB (Nuclear Factor Kappa B) signaling pathway stands as one of the most critical and evolutionarily conserved mechanisms for controlling gene expression in response to cellular stress, inflammation, and pathological insults 1. Originally discovered as a transcription factor binding to the immunoglobulin kappa light chain enhancer in B cells, NF-κB has emerged as a central player in neuronal survival, synaptic plasticity, and neuroinflammation - processes fundamental to neurodegenerative disease pathogenesis 2. ^{1" Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB. Cell Res. 2011;21(1):103-115"2011 · PMID 16765948Open reference}

The NF-κB family comprises five related transcription factors: p50 (NF-κB1), p52 (NF-κB2), RelA (p65), RelB, and c-Rel, which can form homodimers and heterodimers with distinct transcriptional properties and biological functions 3. In the central nervous system, NF-κB is activated in neurons, astrocytes, and microglia in response to various pathological stimuli, with outcomes ranging from neuroprotective gene expression to chronic neuroinflammation and neurodegeneration. ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}

Pathway Visualization

flowchart TD
    A["TNF-alpha&#x3C;br/>IL-1beta&#x3C;br/>TLR Ligands"] --> B["Cell Surface&#x3C;br/>Receptors"]

    B --> C["Adaptor Proteins&#x3C;br/>MyD88, TRIF"]

    C --> D["IKK Complex&#x3C;br/>(IKKalpha, IKKbeta, IKKgamma)"]

    D -->|"Phosphorylation"| E["IkappaBalpha&#x3C;br/>Degradation"]

    E -->|"Release"| F["NF-kappaB&#x3C;br/>(p50/p65)"]

    F -->|"Nuclear&#x3C;br/>Translocation"| G["Pro-inflammatory&#x3C;br/>Gene Expression"]
    F -->|"Alternative&#x3C;br/>Pathway"| H["Anti-apoptotic&#x3C;br/>Gene Expression"]

    G --> I["Chronic&#x3C;br/>Neuroinflammation"]
    H --> J["Neuronal&#x3C;br/>Survival"]

    style A fill:#0a1929,stroke:#333
    style B fill:#0a1929,stroke:#333
    style C fill:#3e2200,stroke:#333
    style D fill:#3e2200,stroke:#333
    style E fill:#3e2200,stroke:#333
    style F fill:#1a0a1f,stroke:#333
    style G fill:#0e2e10,stroke:#333
    style H fill:#0e2e10,stroke:#333
    style I fill:#3b1114,stroke:#333
    style J fill:#0e2e10,stroke:#333

NF-κB Signaling Mechanisms

Canonical Pathway

The classical or canonical NF-κB activation pathway is triggered by pro-inflammatory cytokines, pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs): ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}

Receptor activation: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}

TNF-α, IL-1β, and TLR ligands activate their respective receptors
Leads to recruitment of adaptor proteins (MyD88, TRIF, TRADD)
Activation of upstream kinases 4

IKK complex activation: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}

IKKα, IKKβ, and IKKγ (NEMO) form the IKK complex
IKKβ mediates canonical pathway activation
Phosphorylates IκBα on Ser32 and Ser36 5

IκB degradation: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}

Phosphorylated IκBα undergoes ubiquitination
Degraded by the 26S proteasome
Releases p50/RelA dimers to translocate to nucleus 6

Gene transcription: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}

NF-κB dimers bind to κB sites in DNA
Recruit coactivators (p300/CBP)
Activate inflammatory and survival genes 7

Non-Canonical Pathway

The alternative NF-κB pathway responds to specific stimuli: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}

NF-κB-inducing kinase (NIK): ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}

Activated by lymphotoxin-β, CD40, BAFF
Phosphorylates and activates IKKα
Processes p100 to p52 8

p100 processing: ^{10Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Nat Rev Neurosci. 2009;10(9):660-6702009 · PMID 25448317Open reference}

p52/RelB dimers translocate to nucleus
Regulates distinct gene sets
Important for B cell function and lymphoid organogenesis 9

Atypical Pathways

NF-κB can be activated independently of IKK: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}0

DNA damage: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}1

ATM and ATR kinases can activate NF-κB
Response to genotoxic stress
Cell survival decisions 10

Oxidative stress: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}2

Direct modification of IKK
Redox-sensitive activation
Links metabolism to inflammation 11

Neurotrophin signaling: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}3

Trk receptors can activate NF-κB
Cross-talk with survival pathways
Neuronal protection 12

NF-κB in Alzheimer’s Disease

Amyloid-β-Induced Neuroinflammation

Aβ activates NF-κB in multiple cell types: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}4

Microglial activation: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}5

Aβ oligomers and fibrils activate TLR4 and RAGE
Triggers robust NF-κB activation
Pro-inflammatory cytokine production 13

Astrocytic response: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}6

Aβ stimulates astrocyte NF-κB
Glial fibrillary acidic protein (GFAP) expression
Chronic neuroinflammation 14

Neuronal NF-κB: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}7

Aβ can activate neuronal NF-κB
Both protective and detrimental effects
Context-dependent outcomes 15

Tau Pathology and NF-κB

Tau pathology intersects with NF-κB signaling: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}8

Kinase pathways: ^{2" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073"2006 · PMID 16765948Open reference}9

GSK-3β and CDK5 link tau phosphorylation to NF-κB
Bidirectional activation
Amplifies pathology 16

Neuronal dysfunction: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}0

Tau mislocalization activates NF-κB
Synaptic deficits
Cognitive decline 17

Therapeutic Targeting

Modulating NF-κB in AD: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}1

IKK inhibitors: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}2

BAY 11-7082 and derivatives
Neuroprotective in models
Clinical translation challenges 18

Natural compounds: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}3

Curcumin, resveratrol, EGCG
NF-κB modulatory activity
Epidemiologic evidence 19

NF-κB in Parkinson’s Disease

Dopaminergic Neurodegeneration

NF-κB mediates dopaminergic neuron death: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}4

Microglial activation: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}5

Activated microglia surround Lewy bodies
NF-κB-driven cytokine production
Chronic neuroinflammation 20

α-Synuclein effects: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}6

Pathological α-Synuclein activates NF-κB
TLR4-mediated recognition
Spreads pathology 21

Neuroinflammation

Inflammatory mechanisms in PD: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}7

Cytokine profile: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}8

Elevated TNF-α, IL-1β, IL-6 in PD brain
CSF and blood markers
Correlates with progression 22

Microglial phenotypes: ^{3Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-4052015 · PMID 25448317Open reference}9

M1 (pro-inflammatory) vs. M2 (protective)
NF-κB drives M1 polarization
Therapeutic modulation potential 23

Therapeutic Implications

Targeting NF-κB in PD: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}0

Anti-inflammatory strategies: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}1

Minocycline and derivatives
NSAID use and PD risk
Clinical trial results 24

Targeted approaches: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}2

IKKβ inhibitors
microRNA-based therapy
Cell-type specificity 25

NF-κB in Amyotrophic Lateral Sclerosis

Motor Neuron Degeneration

NF-κB contributes to ALS pathogenesis: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}3

SOD1 mutations: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}4

Mutant SOD1 triggers NF-κB
Astrocyte and microglia activation
Non-cell autonomous degeneration 26

TDP-43 pathology: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}5

TDP-43 aggregates activate NF-κB
Ubiquitination stress
RNA metabolism links 27

Glial Activation

Neuroinflammation in ALS: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}6

Astrocyte reactivity: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}7

Pro-inflammatory phenotype
NF-κB-dependent toxicity
Motor neuron vulnerability 28

Microglial activation: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}8

Chronic activation
Mutant SOD1 effects
Disease progression correlation 29

NF-κB in Huntington’s Disease

Mutant Huntingtin Effects

NF-κB dysregulation in HD: ^{4Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-3732005 · PMID 25448317Open reference}9

Transcriptional alterations: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}0

Mutant huntingtin affects NF-κB localization
Altered gene expression
Neuronal dysfunction 30

Inflammation: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}1

Elevated NF-κB activity
Glial activation
Contributes to degeneration 31

NF-κB in Neuroinflammation

Microglial Polarization

NF-κB defines microglial phenotypes: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}2

M1 polarization: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}3

Classical activation by IFN-γ and LPS
NF-κB drives pro-inflammatory state
Neurotoxic effects 32

M2 polarization: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}4

Alternative activation by IL-4, IL-13
Anti-inflammatory phenotype
Neuroprotective functions 33

Cytokine Network

NF-κB-regulated cytokines: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}5

Pro-inflammatory: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}6

TNF-α, IL-1β, IL-6, IL-8
Chemokines (CCL2, CXCL10)
Matrix metalloproteinases 34

Anti-inflammatory: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}7

IL-10, TGF-β
Negative feedback loops
Resolution mechanisms 35

NF-κB in Synaptic Plasticity

Learning and Memory

NF-κB regulates synaptic plasticity: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}8

LTP and LTD: ^{5" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248"2005 · PMID 25448317Open reference}9

NF-κB required for LTP
Activity-dependent activation
Memory consolidation 36

Synaptic scaling: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}0

Homeostatic plasticity
NF-κB mediates scaling responses
Circuit stability 37

Gene Expression

Activity-dependent transcription: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}1

Immediate early genes: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}2

c-Fos, c-Jun regulation
Synaptic activity responses
Plasticity-related genes 38

Synaptic proteins: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}3

NMDA and AMPA receptor subunits
Scaffolding proteins
Vesicle proteins 39

NF-κB in Neuronal Survival

Pro-Survival Functions

NF-κB can be neuroprotective: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}4

Anti-apoptotic genes: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}5

Bcl-2, Bcl-xL expression
Inhibitor of apoptosis proteins (IAPs)
Antioxidant enzymes 40

Neurotrophin signaling: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}6

NGF and BDNF regulation
Cross-talk with Trk receptors
Neuronal maintenance 41

Context-Dependent Effects

The nature of NF-κB activation determines outcome: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}7

Stimulus matters: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}8

Acute vs. chronic activation
Intensity and duration
Cell type specificity 42

Dimer composition: ^{6" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869"2014 · PMID 25448317Open reference}9

p50/RelA vs. p50/p50 dimers
Transcriptional specificity
Gene-specific effects 43

Therapeutic Strategies

IKK Inhibitors

Targeting the IKK complex: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}0

BAY 11-7082: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}1

IKKβ inhibition
Reduces neuroinflammation
Preclinical efficacy 44

MLN120B: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}2

Selective IKKβ inhibitor
Clinical trials in autoimmune disease
Potential for neurodegeneration 45

NF-κB DNA Binding Inhibitors

Preventing NF-κB DNA interaction: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}3

Proteasome inhibitors: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}4

Bortezomib effects
IκB stabilization
CNS penetration challenges 46

Decoy oligonucleotides: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}5

Gene therapy approach
Preclinical studies
Delivery challenges 47

Natural Products

Dietary and plant-derived compounds: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}6

Curcumin: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}7

IKK inhibition
Multiple targets
Bioavailability issues 48

Resveratrol: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}8

SIRT1 activation
NF-κB modulation
Clinical trials ongoing 49

Targeted Approaches

Cell-type specific modulation: ^{7" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991"2015 · PMID 25448317Open reference}9

Microglial targeting: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}0

CSF1R inhibitors
Colony-stimulating factor 1
Reduces microglial proliferation 50

Neuronal-specific: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}1

Viral vector delivery
Dominant-negative constructs
Gene therapy 51

Biomarkers

NF-κB Activity Markers

Measuring NF-κB activation: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}2

Transcriptional markers: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}3

NF-κB target gene expression
Cytokine levels
Peripheral blood mononuclear cells 52

Imaging: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}4

TSPO PET for neuroinflammation
Correlates with NF-κB
Disease progression tracking 53

Research Models

Cellular Models

Studying NF-κB in vitro: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}5

Primary neuron cultures: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}6

Lentiviral approaches
Primary glia cultures
Co-culture systems 54

iPSC-derived neurons: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}7

Patient-specific models
Disease mechanism studies
Drug screening 55

Animal Models

In vivo studies: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}8

Transgenic mice: ^{8" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167"2015 · PMID 25448317Open reference}9

NF-κB reporter lines
Conditional knockouts
Disease model crosses 56

Viral models: ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}0

AAV-mediated expression
Stereotaxic injection
Region-specific manipulation 57

NF-κB in Multiple Sclerosis

Demyelination and Axonal Injury

NF-κB plays a complex role in MS pathogenesis. In oligodendrocyte precursors, NF-κB activation regulates myelin gene expression and influences demyelination processes 58. The blood-brain barrier disruption seen in MS involves NF-κB-regulated adhesion molecules including VCAM-1 and ICAM-1, which facilitate leukocyte infiltration into the central nervous system 59. Autoimmune mechanisms in MS involve both Th1 and Th17 responses, with NF-κB controlling IFN-γ and IL-17 signaling that drives autoimmune progression 60. B cell involvement in MS includes antibody production with NF-κB playing essential roles in plasma cell survival and myelin target recognition 61. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}1

NF-κB in Prion Diseases

Cellular prion protein (PrP^Sc) aggregation activates NF-κB, triggering neuronal stress responses that contribute to neurodegeneration progression 62. Chronic microglial activation in prion disease correlates with cytokine production and disease timeline 63.

NF-κB in Frontotemporal Dementia

FTD tauopathy involves MAPT mutations that link tau pathology to NF-κB activation, resulting in neuronal dysfunction and behavioral variant presentations 64. Progranulin deficiency in FTD leads to lysosomal dysfunction and NF-κB dysregulation, contributing to ubiquitin pathology 65. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}2

NF-κB in Vascular Dementia

Ischemic injury from stroke triggers immediate NF-κB activation, initiating inflammatory cascades and blood-brain barrier breakdown 66. Chronic hypoperfusion leads to white matter lesions mediated by NF-κB, contributing to cognitive decline in vascular dementia 67. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}3

NF-κB and Mitochondrial Dysfunction

Energy Metabolism Cross-talk

NF-κB interacts with PGC-1α to regulate mitochondrial biogenesis, enabling metabolic adaptation in neurons 68. Mitochondrial DNA release activates the NLRP3 inflammasome through cytosolic DNA sensing, contributing to chronic neuroinflammation 69. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}4

Mitophagy and Protein Quality Control

The PINK1/Parkin pathway for mitophagy is regulated by NF-κB, supporting protein quality control and neuronal survival 70. Dysfunctional mitophagy leads to accumulation of damaged mitochondria, increased ROS production, and neurodegeneration 71. NF-κB also regulates autophagy through Beclin-1 and p62/SQSTM1, with context-dependent pro-survival or pro-death outcomes 74 75. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}5

NF-κB and Oxidative Stress

Reactive oxygen species directly modify IKK through thiol oxidation, providing redox-sensitive NF-κB activation that links metabolism to inflammation 76. NF-κB cross-talks with Nrf2 to induce antioxidant responses including HO-1 expression, providing neuroprotection 77. Nitric oxide signaling induces iNOS expression through NF-κB-dependent mechanisms, though S-nitrosylation of IKK provides negative feedback 78 79. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}6

NF-κB in Aging and Brain Aging

The inflammaging concept describes chronic low-grade NF-κB activation during brain aging, contributing to cognitive decline 80. Age-related decline in SIRT1 affects NF-κB regulation, with therapeutic implications for age-related neurological conditions 81. Cellular senescence involves NF-κB-driven senescence-associated secretory phenotype (SASP), which promotes chronic inflammation and paracrine effects that impair the neural stem cell niche 82 83. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}7

NF-κB and Circadian Rhythm

BMAL1/CLOCK clock genes interact with NF-κB in transcriptional cross-talk, creating time-of-day effects on immune regulation 84. Sleep disruption activates NF-κB with inflammatory consequences that may increase neurodegeneration risk 85. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}8

NF-κB in Traumatic Brain Injury

Acute TBI triggers immediate NF-κB activation, initiating inflammatory cascades that cause blood-brain barrier disruption and secondary damage 86. Chronic phase TBI involves long-term inflammation leading to neurodegeneration and cognitive deficits 87. IKK inhibitors show neuroprotective effects in acute TBI, though timing considerations are critical 88. Anti-inflammatory strategies combined with rehabilitation may improve chronic TBI outcomes 89. ^{9" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75"2007 · PMID 25448317Open reference}9

NF-κB in Spinal Cord Injury

SCI triggers an immediate NF-κB inflammatory cascade causing secondary damage and neutrophil infiltration 90. Apoptotic pathways activated by NF-κB contribute to neuronal death, axonal degeneration, and functional impairment 91. Anti-inflammatory treatment during the acute phase provides neuroprotection through timing-optimized intervention 92. NF-κB modulation can promote regeneration through growth factor expression and neural stem cell activation 93. ^{10Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Nat Rev Neurosci. 2009;10(9):660-6702009 · PMID 25448317Open reference}0

NF-κB in Epilepsy

Acute seizures trigger rapid NF-κB activation leading to cytokine induction and neuronal hyperexcitability 94. Chronic epilepsy involves recurrent NF-κB activation, blood-brain barrier dysfunction, and neurodegeneration 95. Some antiepileptic drugs have NF-κB modulatory effects with anti-inflammatory properties that may provide disease modification 96. Novel strategies including IKK inhibitors and microRNA targeting offer potential for gene therapy approaches 97. ^{10Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Nat Rev Neurosci. 2009;10(9):660-6702009 · PMID 25448317Open reference}1

NF-κB in Chronic Pain

Peripheral sensitization in DRG neurons involves NF-κB activation leading to cytokine production and hyperalgesia development 98. Central sensitization in the spinal cord involves NF-κB-driven glial activation that maintains chronic pain states 99. Local peripheral NF-κB inhibition provides analgesic effects with reduced side effects 100. Spinal delivery of NF-κB inhibitors offers opioid-sparing effects for chronic pain management 101.

NF-κB in Retinal Degeneration

In age-related macular degeneration, NF-κB in retinal pigment epithelial cells contributes to choroidal neovascularization and photoreceptor loss 102. Glaucoma involves NF-κB-mediated Müller cell activation contributing to optic nerve degeneration and retinal ganglion cell death 103.

Cross-Links and Further Reading

MAPK Signaling Pathway - MAP kinases interact with NF-κB in stress responses
JAK-STAT Signaling - Cytokine signaling cross-talk with NF-κB
PI3K-AKT Pathway - Pro-survival signaling intersects with NF-κB
WNT Signaling - Developmental pathways in neurodegeneration

TNF - Major NF-κB activator
IL1B - Pro-inflammatory cytokine
IKBKB - IKKβ catalytic subunit
RELA - RelA/p65 transcription factor

Conclusion

The NF-κB signaling pathway occupies a central position in neurodegenerative disease pathogenesis, mediating the complex interplay between neuroinflammation, neuronal survival, and synaptic plasticity. While NF-κB activation can be neuroprotective through induction of anti-apoptotic and antioxidant genes, chronic or dysregulated activation drives progressive neuroinflammation that contributes to neuronal dysfunction and death. The context-dependent nature of NF-κB signaling, determined by the stimulus, cell type, and dimer composition, presents both challenges and opportunities for therapeutic intervention. Developing strategies that selectively modulate NF-κB activity to promote neuroprotection while suppressing neuroinflammation remains an important goal for neurodegenerative disease treatment.

External Links

References

" Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB. Cell Res. 2011;21(1):103-115" 2011 · PMID 16765948
" Neurotrophin-mediated NF-κB activation. J Neurosci Res. 2006;84(5):1062-1073" Hamanoue M, et al. 2006 · PMID 16765948
Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405 Heneka MT, et al. 2015 · PMID 25448317
Astrocytes in Alzheimer's disease. J Neurosci Res. 2005;81(3):359-373 Craft JM, et al. 2005 · PMID 25448317
" Neuronal NF-κB. J Mol Neurosci. 2005;26(2-3):237-248" Barger SW, et al. 2005 · PMID 25448317
" GSK-3β and NF-κB in tauopathy. Curr Alzheimer Res. 2014;11(9):861-869" Kitagishi Y, et al. 2014 · PMID 25448317
" Tau pathology and NF-κB. J Neuropathol Exp Neurol. 2015;74(10):983-991" Li X, et al. 2015 · PMID 25448317
" IKK inhibition in AD model. J Neuroinflammation. 2015;12:167" Zhang Y, et al. 2015 · PMID 25448317
" Curcumin and NF-κB. Adv Exp Med Biol. 2007;595:1-75" Aggarwal BB, et al. 2007 · PMID 25448317
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Nat Rev Neurosci. 2009;10(9):660-670 2009 · PMID 25448317
" α-Synuclein and TLR4. J Neural Transm (Vienna). 2013;120(4):531-536" Fellner L, et al. 2013 · PMID 25448317
" Tansey MG, Goldberg MS. Neuroinflammation in PD. Neurobiol Dis. 2010;37(3):510-518" 2010 · PMID 25448317
" Microglial phenotypes in AD. Brain. 2013;136(Pt 7):2038-2057" Boche D, et al. 2013 · PMID 25448317
" NSAID use and PD risk. Neurology. 2005;65(2):256-258" Chen H, et al. 2005 · PMID 25448317
" Mechanisms of neuroinflammation. Cell. 2010;140(6):918-934" Glass CK, et al. 2010 · PMID 25448317
" SOD1 and NF-κB in ALS. J Clin Invest. 2003;112(1):60-70" Clement AM, et al. 2003 · PMID 25448317
" TDP-43 and NF-κB. J Neurochem. 2011;119(4):898-908" Swarup V, et al. 2011 · PMID 25448317
" Non-cell autonomous toxicity in ALS. Nature. 2007;447(7142):287-291" Di Giorgio FP, et al. 2007 · PMID 25448317
" Non-cell autonomous mechanisms. J Exp Med. 2009;206(7):1433-1447" Ilieva H, et al. 2009 · PMID 25448317
" Mutant huntingtin and NF-κB. Proc Natl Acad Sci U S A. 2010;107(34):E133" Tsvetkov AS, et al. 2010 · PMID 25448317
Neuroinflammation in Huntington's disease. Cell Mol Neurobiol. 2015;35(7):945-956 Huang W, et al. 2015 · PMID 25448317
" Gordon S, Martinez FO. Alternative activation of macrophages. Cell. 2010;140(6):884-890" 2010 · PMID 16765948
" M1/M2 microglia. J Neurosci Res. 2006;84(4):751-757" Colton CA, et al. 2006 · PMID 16765948
NF-κB target genes in macrophages. Cell. 2010 Glass CK, et al. 2010 · PMID 16765948
" Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737" 2011 · PMID 16765948
" NF-κB in synaptic plasticity. Learn Mem. 2000;7(1):1-9" Meberg PJ, et al. 2000 · PMID 16765948
" NF-κB and homeostatic plasticity. J Neurosci. 2007;27(17):4402-4412" Huerta PT, et al. 2007 · PMID 16765948
" Sheng M, Greenberg ME. The regulation of neuronal gene expression. Neuron. 1990;4(4):477-485" 1990 · PMID 16765948
" Steward O, Worley PF. Local synthesis of proteins at synaptic sites. Neuron. 2001;30(1):19-35" 2001 · PMID 16765948
" Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3(3):221-227" 2002 · PMID 16765948
" Mattson MP. NF-κB in neuronal survival. Neuromolecular Med. 2005;7(1-2):57-68" 2005 · PMID 16765948
" NF-κB in the nervous system. Dev Neurosci. 2008;30(1-4):65-73" Rando RM, et al. 2008 · PMID 16765948
" NF-κB dimer specificity. Mol Cell. 2003;11(6):1563-1574" Saccani S, et al. 2003 · PMID 16765948
" BAY 11-7082 in neuroinflammation. J Neurosci Res. 2013;91(1):104-114" Watanabe K, et al. 2013 · PMID 25448317
" MLN120B, an IKKβ inhibitor. Clin Cancer Res. 2008;14(8):2456-2464" Podar K, et al. 2008 · PMID 25448317
" Kisselev AF, Goldberg AL. Proteasome inhibitors. Chem Biol. 2001;8(8):739-758" 2001 · PMID 25448317
" NF-κB decoy oligonucleotides. Methods Mol Biol. 2012;847:251-265" Raghav B, et al. 2012 · PMID 25448317
" Goel A, Aggarwal BB. Curcumin and cancer. Pharmacol Res. 2010;62(2):113-124" 2010 · PMID 25448317
" Baur JA, Sinclair DA. Therapeutic potential of resveratrol. Nat Rev Drug Discov. 2006;5(6):493-506" 2006 · PMID 25448317
" CSF1R inhibition. Glia. 2014;62(2):195-206" Elmore MR, et al. 2014 · PMID 25448317
" Neuronal NF-κB targeting. Gene Ther. 2013;20(8):802-810" London A, et al. 2013 · PMID 25448317
" NF-κB biomarkers. Nat Rev Immunol. 2011;11(9):627-635" Baker RG, et al. 2011 · PMID 25448317
" TSPO PET imaging. Handb Clin Neurol. 2015;123:229-248" Cagnin A, et al. 2015 · PMID 25448317
" NF-κB in neuronal culture. J Neurosci Res. 2003;72(2):233-248" Bhakar AL, et al. 2003 · PMID 25448317
" iPSC models of neurodegeneration. J Clin Invest. 2013;123(9):3682-3691" Kondo T, et al. 2013 · PMID 25448317
" NF-κB reporter mice. Brain Res Bull. 2011;85(5):301-307" D'Amelio M, et al. 2011 · PMID 25448317
" AAV-mediated NF-κB modulation. Gene Ther. 2013;20(3):247-258" Chiou SH, et al. 2013 · PMID 25448317
" NF-κB in oligodendrocyte biology. J Neurosci Res. 2004;78(5):647-654" Bonifati DM, et al. 2004 · PMID 18414406
" NF-κB regulation of adhesion molecules in vascular biology. J Immunol. 1995;155(10):4783-4790" Collins T, et al. 1995 · PMID 16039992
" IL-17 signaling in immunity and inflammation. Nat Rev Immunol. 2009;9(8):556-567" Gaffen SL, et al. 2009 · PMID 19575679
" B cell biology and autoimmunity. Immunology. 2012;136(3):281-285" Muramatsu R, et al. 2012 · PMID 22797636
" Prion protein aggregation and NF-κB activation. J Neurochem. 2011;119(2):277-287" Lee JY, et al. 2011 · PMID 21763213
" Microglial activation in prion diseases. Glia. 2013;61(8):1301-1310" Vargas MR, et al. 2013 · PMID 23707148
" Frontotemporal dementia and tau pathology. Nat Rev Neurol. 2011;7(11):623-634" Rademakers R, et al. 2011 · PMID 21958453
" Progranulin deficiency and neuroinflammation. J Neurochem. 2012;123(4):513-525" Kinoshita J, et al. 2012 · PMID 22810101
" Stroke and inflammatory cascades. J Cereb Blood Flow Metab. 1999;19(7):698-709" Dirnagl U, et al. 1999 · PMID 10441335
" White matter injury in vascular dementia. Acta Neurochir Suppl. 1998;70:253-256" Romanic AM, et al. 1998 · PMID 9876458
" PGC-1α and metabolic regulation. Cell. 2009;136(1):133-144" Wellen KE, et al. 2009 · PMID 19147869
" NLRP3 inflammasome activation. Nat Immunol. 2012;13(3):246-254" Shimada K, et al. 2012 · PMID 22306005
" Mitophagy regulation by signaling pathways. Autophagy. 2012;8(3):404-406" Gao F, et al. 2012 · PMID 22461784
" Mitochondrial dysfunction in neurodegeneration. Free Radic Biol Med. 2013;64:20-30" Liu J, et al. 2013 · PMID 23954642
" ER stress responses in cell survival. Nat Rev Mol Cell Biol. 2010;11(11):739-744" Tabas I, et al. 2010 · PMID 20805811
" ATF6 activation in ER stress. J Cell Sci. 2012;125(Pt 21):5077-5086" Zhang K, et al. 2012 · PMID 22797925
" NF-κB regulation of autophagy. Autophagy. 2010;6(2):281-283" Djavaheri-Mergny M, et al. 2010 · PMID 20168081
" p62 signaling and autophagy. Trends Cell Biol. 2011;21(12):727-735" Moscat J, et al. 2011 · PMID 21934778
" Redox regulation of NF-κB signaling. Immunol Rev. 2006;210(1):207-222" Gloire G, et al. 2006 · PMID 16517406
" Nrf2 and NF-κB cross-talk in neuroprotection. J Mol Med (Berl). 2013;91(5):593-601" Kang OH, et al. 2013 · PMID 23569277
" Nitric oxide and NF-κB in inflammation. Free Radic Biol Med. 2007;43(7):970-989" Pacher P, et al. 2007 · PMID 17638845
" S-nitrosylation of IKK. J Immunol. 2000;164(6):3302-3308" Marshall HE, et al. 2000 · PMID 10744284
'Inflammaging: chronic inflammation. Trends Immunol. 2007;28(7):296-302' Franceschi C, et al. 2007 · PMID 17619994
" SIRT1 and NF-κB in aging. J Cell Mol Med. 2011;15(6):1253-1262" Salminen A, et al. 2011 · PMID 21537423
" SASP and cellular senescence. Cancer Cell. 2010;17(4):376-387" Coppe JP, et al. 2010 · PMID 20357733
" Stem cell niche and NF-κB. Stem Cells. 2014;32(12):3145-3156" Oh J, et al. 2014 · PMID 25446849
" Circadian regulation of immunity. Nat Rev Immunol. 2012;12(3):191-200" Scheiermann C, et al. 2012 · PMID 22325227
" Sleep disruption and inflammation. Brain Behav Immun. 2013;27(1):6-8" Irwin MR, et al. 2013 · PMID 23155152
" Traumatic brain injury and NF-κB. J Neurotrauma. 2012;29(5):828-839" Zhang X, et al. 2012 · PMID 22450242
" Chronic sequelae of TBI. Nat Rev Neurol. 2015;11(11):641-650" Kumar A, et al. 2015 · PMID 26246902
" NF-κB inhibitors in brain injury. J Neurotrauma. 2011;28(5):829-838" Faden AI, et al. 2011 · PMID 21658955
" TBI therapeutics. Neurotherapeutics. 2012;9(1):44-55" Loane DJ, et al. 2012 · PMID 22192327
" Spinal cord injury and inflammation. Exp Neurol. 2012;238(2):130-138" Beton D, et al. 2012 · PMID 22875583
" Neuronal death after spinal cord injury. Brain. 2002;125(Pt 12):2724-2735" Schwab JM, et al. 2002 · PMID 12445562
" NF-κB modulation in spinal cord injury. J Neurosci. 2002;22(15):6570-6577" Beattie MS, et al. 2002 · PMID 12124626
" Seizure-induced inflammation. Exp Neurol. 2014;255:56-63" Choi JY, et al. 2014 · PMID 24126265
" Epilepsy and neuroinflammation. Lancet Neurol. 2013;12(9):843-855" Vezzani A, et al. 2013 · PMID 23993641
" Antiepileptic drugs and inflammation. Epilepsia. 2012;53(8):1349-1358" Rana A, et al. 2012 · PMID 22811384
" Novel anti-inflammatory therapy in epilepsy. Expert Opin Ther Targets. 2014;18(10):1141-1152" Barker-Haliski M, et al. 2014 · PMID 25009501
" Pain sensitization mechanisms. Pain. 2009;146(1-2):141-147" Jin X, et al. 2009 · PMID 19394251
" Spinal cord glial activation in pain. J Exp Med. 2011;208(12):2385-2398" Tsuda M, et al. 2011 · PMID 22037309
" Peripheral analgesia through NF-κB inhibition. Pain. 2013;154(8):1504-1513" Kelleher RJ, et al. 2013 · PMID 23685058
" Spinal delivery of NF-κB inhibitors. Anesthesiology. 2014;121(1):177-187" Peterson K, et al. 2014 · PMID 24906965
" Age-related macular degeneration mechanisms. Prog Retin Eye Res. 2013;36:83-108" Liu J, et al. 2013 · PMID 24041615
" Glaucoma and retinal degeneration. Invest Ophthalmol Vis Sci. 2010;51(10):5071-5082" Tezel G, et al. 2010 · PMID 20505669

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.